No. 85

December 2012

Headline News Innovation and Development

Applied Technology

Basic Science

Exchanges with Taiwan, Hong Kong and Macau

Bioscience International Cooperation Brief News Geoscience


Fully Human mAbs against Influenza A Virus Obtained

The 2009 pandemic H1N1 influenza virus caused huge loss to human society and became the main epidemic strain in recent years. Under the supervision of Prof. Sun Bing from the Molecular Virology Unit, Institut Pasteur of Shanghai, Hu Weibin and Chen Aizhong, isolated neutralizing antibodies against this virus. They separated pandemic H1N1 HA-specific memory B cells from a 2009 pandemic H1N1 influenza vaccine recipient with three surface markers: CD19, IgG, and HA-specific BCR, and identified the antibody variable genes of these memory B cells with single-cell RT-PCR. A panel of fully human monoclonal antibodies (mAbs) was obtained. The data showed that seven mAbs exhibited neutralizing activity against influenza A viruses of H1, H3, H5, H7 and H9 subtypes. Epitope mapping revealed that the seven mAbs targeted the HA2 fragment of the HA stem region, including a linear epitope locates on the fusion peptide and other conformational epitopes. Mechanism study indicated that these antibodies could inhibit the membrane fusion mediated by HA2 during virus entry. This finding may be helpful in the development of therapeutic antibodies and the design of universal vaccines for influenza A virus. This work was a collaboration between the Institute Pasteur of Shanghai and Antibody Research Center, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences. The research article entitled "Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient" was published on Virology on Oct. 16, 2012.

Progress Made in Ocular Gene Drug Delivery

Ocular diseases are usually treated with a topical application of drug solutions (i.e. eye drops). These traditional dosage forms account for nearly 90% of currently available marketed formulations due to their simplicity, safety and acceptance by patients. However, ocular physiological barriers and the poor water solubility of drug candidates present a number of problems for the development of ocular drug delivery systems. Recently, various ophthalmic drug delivery strategies aim at improving the bioavailability of poor soluble ocular drugs have emerged. New technological advances and developments of ocular drug delivery have been reviewed by Dr. Gan Yong¡¯s group from the Shanghai Institute of Materia Medica. Among them, lipid-based nanocarriers exhibit a variety of potential advantages as delivery systems for ocular administration. A novel ocular gene drug delivery system of cationic core-shell liponanoparticles (DLCS-NP) has been developed by Dr. Gan Yong¡¯s group. Researchers (Jiang Ming and Gan Li, et al) designed the DLCS-NP by the hydration of a thin lipid ?lm with a chitosan nanoparticle (CS-NP) suspension, followed by the post-insertion of the cationic phospholipid DOTAP (1,2-dioleoyl-3- trimethylammonium-propane). This specific delivery strategy has multiple functions, including better DNA protecting effect, good cellular uptake efficiency with multiple endocytic pathways, and endolysosome escaping ability. This research has been published on Biomaterials (2012, 33: 7621-7630).

Other Issues
Eighty-forth Issue (October 2012)
Eighty-third Issue (August 2012)
Eighty-second Issue (June 2012)
Eighty-first Issue (April 2012)
Eightieth Issue (February 2012)
Seventy-ninth Issue (December 2011)
Seventy-eighth Issue (October 2011)
Seventy-seventh Issue (August 2011)
Seventy-sixth Issue (June 2011)
Seventy-fifth Issue (April 2011)
Seventy-forth Issue (February 2011)
Seventy-third Issue (December 2010)
Seventy-second Issue (October 2010)
Seventy-first Issue (August 2010)
Seventieth Issue (June 2010)
Sixty-nineth Issue (April 2010)
Sixty-eighth Issue (February 2010)

Sixty-seventh Issue (December 2010)

Sixty-sixth Issue (October 2009)
Sixty-fifth Issue (August 2009)
Sixty-fourth Issue (June 2009)
Sixty-third Issue (April 2009)
Sixty-second Issue (February 2009)
Sixty-first Issue (December 2008)
Sixtieth Issue (October 2008)
Fifty-nineth Issue (August 2008)
Fifty-eighth Issue (June 2008)
Fifty-seventh Issue (April 2008)
Fifty-sixth Issue (February 2008)
Fifty-fifth Issue (December 2007)
Fifty-fourth Issue (October 2007)
Fifty-third Issue (August 2007)
Fifty-second Issue (June 2007)
Fifty-first Issue (April 2007)
Fiftith Issue (Feb. 2007)
Fourty-nineth Issue (December, 2006)
Fourty-eighth Issue (Ocboter, 2006)
Fourty-seventh Issue (August, 2006)
Fourty-sixth Issue (June, 2006)
Fourty-fifth Issue (April, 2006)
Fourty-fourth Issue (February, 2006)

copyright © 1998-2015
CAS Newsletter Editorial Board: 52, Sanlihe Road, Beijing 100864, CHINA